STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Peptide

Insulin

Also known as

Insulin (research/bodybuilding discourse) · slin (slang) · exogenous insulin · Humalog / insulin lispro (rapid analog discussions) · Novolog / NovoRapid / insulin aspart (rapid analog discussions) · Apidra / insulin glulisine (rapid analog discussions) · Humulin R / Novolin R / regular insulin (short-acting) · Lantus / insulin glargine (basal long-acting talk) · Levemir / insulin detemir (basal talk) · Tresiba / insulin degludec (ultra-long basal contrast) · Humulin N / NPH (intermediate; less common in pulse “slin” charts)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Peptide Some talk Systemic Product-specific; primarily subcutaneous Metabolic hormones

Systemic — whole-body glucose disposal, amino-acid handling, and anti-lipolytic storage physiology.

What people say Insulin is a blood-glucose-regulating peptide hormone used medically for diabetes. Bodybuilding discussions focus on temporary fullness and recovery impressions.Food, training and other hormones confound those accounts; they are not a safe-use protocol. Doses people talk about Insulin dosing is formulation- and person-specific. Community bodybuilding charts do not establish a safe beginner dose.Rapid, regular and basal products have different action profiles. Insulin can cause life-threatening hypoglycemia; matching a forum dose with a meal does not make it safe. The original dose discussion remains in the full notes.

Half-life & effect duration

Half-life in the body
  • Humalog / lispro · under the skinAbout 1 hour
  • Tresiba / degludec · steady stateAbout 25 hours
Felt duration people report
  • One bodybuilding accountWorkout fullness through the day alongside food, training and other hormones
  • Same accountLow-blood-sugar episodes also reported
Timing context & sources
How it may feel Accounts describe temporary workout fullness; one reports weakness and shaking during hypoglycemia. Other warning symptoms include sweating, hunger, confusion or blurred vision. Feeling normal does not establish that insulin has stopped acting.
Cycles people discuss Reports include training-day use within 2–4+ or roughly 4–12-week bulking blocks, and separate ongoing basal-insulin discussion. These are community patterns, not validated safe nonmedical cycles. Timing Meals, training and formulation change the risk window; a blood half-life or subjective feeling is not a safe-use timer. Stacks Testosterone + GH + insulin (“trinity”): Classic advanced bulk narrative — androgens for mass/strength, GH for lipolysis/IGF-1/recovery look, insulin for disposal/fullness and to counter GH’s diabetogenic push. Watch for Hypoglycemia (primary acute risk): Tremor, sweating, hunger, anxiety, confusion, blurred vision; can progress to seizure, loss of consciousness, coma, death.
Related
MK-677MetforminTirzepatideSemaglutide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 1 hour for subcutaneous Humalog (insulin lispro).

Insulin type and route matter; this is not the glucose-lowering action window.

The label separately discusses IV measurements. Do not substitute these numbers for another formulation or use them to time nonmedical use.

  • Humalog prescribing information — DailyMed (opens in a new tab)Humalog §§5.3,12.2,12.3 and storage: variable glucose-lowering action, 30–90-minute serum peak versus PD, severe hypoglycemia and product/container-specific storage. Actual independent label inspection September 6.Repackaged official labeling. The explicit SC comparison is approximately 1 versus 1.5 hours; adjacent 51/55-minute results follow an IV discussion.

Half-life in the body

About 25 hours for subcutaneous Tresiba (insulin degludec) at steady state.

Absorption from the injection site largely determines this much longer value.

A basal insulin is not interchangeable with a rapid insulin. A half-life value is not a safe-use window.

Felt duration people report

One bodybuilding account describes workout fullness through the day, alongside other hormones, food and training.

The same account reports hypoglycemia. Feeling an effect—or feeling normal—does not establish safety.

The report cannot isolate insulin's contribution. Severe hypoglycemia can be life-threatening; this is not a dosing, food-matching or timing protocol.

  • Insulin — first-person community account (opens in a new tab)Comment by biggie_smalls 411; training/fullness and hypoglycemia paragraphsConcurrent testosterone, NPP, growth hormone, supplements, carbohydrate loading and training confound the account. Its dosing instructions and safety reassurances are not adopted.
  • Humalog prescribing information — DailyMed (opens in a new tab)Humalog §§5.3,12.2,12.3 and storage: variable glucose-lowering action, 30–90-minute serum peak versus PD, severe hypoglycemia and product/container-specific storage. Actual independent label inspection September 6.Repackaged official labeling. The explicit SC comparison is approximately 1 versus 1.5 hours; adjacent 51/55-minute results follow an IV discussion.

What people say 10

  • Nutrient partitioning (headline claim): Community asserts carbs and amino acids are driven into muscle rather than fat when insulin is timed with a large peri-workout meal — physiology is real; selective “only muscle” partitioning is oversold. forum
  • Glycogen replenishment / training fullness: Faster refill after depleting sessions when rapid insulin is paired with large carb loads; temporary muscle fullness and vascularity are common early reports. forum
  • Pump / glycogen look: Short-term “full and hard” training-day aesthetics on bulk food — water/glycogen confound large. anecdote
  • High-carb bulk enablement: Advanced logs claim insulin makes very high daily carb intakes more “usable” for recovery; also raises fat-storage risk if surplus is sloppy. forum
  • GH stack synergy narrative: GH can raise glucose and reduce insulin sensitivity; exogenous insulin is discussed as restoring nutrient disposal so high-GH / high-food bulks continue — classic “test + GH + slin” trinity lore. forum
  • Anti-catabolic window: Suppresses muscle protein breakdown and supports the fed anabolic environment post-shot; often cited more carefully than “insulin builds muscle like tren.” trial
  • Amino-acid uptake / BCAA clearance talk: Insulin lowers circulating amino acids (BCAAs especially sensitive in classic physiology) via tissue uptake and reduced proteolysis — used as mechanistic support for PWO protein pairing. trial
  • AAS co-use confound: In one nondiabetic weightlifting case series, ~95% of insulin users also used anabolic steroids and averaged many other PEDs yearly — single-agent credit for size is unreliable. trial
  • Burn / clinical lean-mass context (not gym proof): Controlled insulin protocols after severe burns increased lean mass in clinical settings; reviews note this does not establish hypertrophy benefit for healthy nondiabetic lifters. trial
  • Prevalence / accessibility context: PED reviews cite roughly ~10% of some recreational/professional bodybuilder samples and higher fractions in small older US weightlifting polls reporting insulin use; often obtained from gym networks or (where OTC) pharmacies. trial

Doses people talk about 17

  • Lower secondary-chart report, not a beginner band: Roughly 4–6 IU Humalog/Novolog-class post-workout appears in older bodybuilding guides. A published chart is not evidence of a safe nonmedical starting amount. forum
  • Mid community tables: ~6–10 IU once daily (training days) appears as a frequently discussed mid band in modern secondary protocol summaries. forum
  • Upper common pulse talk: ~10–15 IU rapid/short on training days only in more aggressive charts — still well below some extreme pro lore. forum
  • Multi-meal advanced patterns (anecdote): Some logs describe small boluses with multiple meals (e.g., low-single-digit IU per meal) plus a larger PWO shot — polypharmacy and hypo risk stack. anecdote
  • Carbohydrate-per-IU lore: Forums publish fixed-ratio food rules, but no fixed ratio establishes protection against hypoglycemia. These are a subject of risk discussion, not a usable food-matching formula. forumtrial
  • Meal-matching uncertainty: One first-person account reports hypoglycemia despite repeating the same food-and-shake routine. Prior uneventful use did not predict the next session; a worked insulin/food calculation cannot establish safety. forum
  • Meal-sequencing lore: Legacy charts combine fast carbohydrates, later protein/carbohydrate meals and repeated feeding around supposed action windows. Those sequences are not validated safeguards or a safe injection-to-meal timetable. forum
  • Pre- versus post-workout debate: Recovery/glycogen accounts discuss post-workout use; pump/performance accounts also discuss pre-workout rapid insulin. Exercise and food timing can change hypoglycemia risk; intra-workout carbohydrate lore is not a safety guarantee. forumtrial
  • Older regular-insulin protocol literature: Mike Arnold-class secondary writeups discuss aggressive Humulin R amounts around 15 IU before training with high-molecular-weight carbohydrates. Their first-timer escalation sequences are not clinical dosing or validated safeguards; this card does not provide a step-up procedure. forum
  • Basal (Lantus) discussion: Separate advanced lane — low basal IU with first meal / morning to “cover” high food or GH-related glucose elevation; not the default “slin PWO pulse” starter chart. forum
  • Food-plan warning: Forums repeatedly warn about missing or delayed meals. That protective concern remains important, but having a food plan does not make nonmedical insulin use safe. forumtrial
  • Lower chart report, not an entry dose: Older bodybuilding charts describe roughly 2–4 IU rapid-acting once alongside a large meal. That “start low” label does not establish safe first use; severe hypoglycemia can be life-threatening. forumtrial
  • Past tolerance is not clearance to increase: Forum escalation lore relies on prior uneventful sessions and presumed food matching. Labeling says glucose-lowering effects vary between people and within the same person; those observations do not establish a safe larger amount. forumtrial
  • Mean log figure (older US weightlifting poll): ~10 IU per injection reported as a mean among polled users, with dosing info often word-of-mouth. trial
  • Extreme / ER-adjacent anecdotes: Case literature includes bodybuilders taking very high total IU (e.g., ~70 IU class reports with hypoglycemic convulsions) and viral pro lore of much higher meal/PWO numbers — treated as cautionary extremes, not templates. trial
  • Framing: Community discussion, case-series, and secondary protocol ranges only — not medical advice, not non-diabetic prescriptions, not safety-validated athletic protocols. Individual insulin sensitivity varies widely. forum
  • Common working / modal band: Mid-single to low-double-digit IU per injection; PED reviews summarize short-acting use often ~2–15 IU/dose once daily SC or IM. trial

How it may feel 8

  • Early rapid-insulin discussion: Older charts use 0–15 minutes as onset shorthand and emphasize food planning. Onset is formulation-dependent and need not be felt; no injection-to-food schedule or safe-use countdown follows from that shorthand. forumtrial
  • Later rapid-insulin discussion: The inherited 2–4-hour fading shorthand is not an end-of-danger clock. Delayed hypoglycemia remains possible, including with insufficient or delayed food, continued hard training or alcohol; action varies within and between people. forumtrial
  • Same-day multi-shot patterns: Some advanced logs use pre + post workout or small meal boluses; risk and carb-matching complexity rise sharply. forum
  • Training-day patterns: Community discussion includes event-timed use on hard training days, contrasting it with longer basal coverage. Neither pattern is an established beginner option. forum
  • Days–weeks on a bulk block: Fullness and recovery talk accumulate if food is massive and consistent; fat gain and hypo near-misses are the early negative checkpoints. forum
  • Blood peak versus symptoms: Humalog labeling reports peak serum concentrations around 30–90 minutes in studied subcutaneous exposures, not a universal peak glucose-drop or symptom window. Shaking, sweating, hunger, confusion, irritability and blurred vision remain important warning symptoms. trial
  • Regular (Humulin R-class) feel: Slower onset (~30–60 min), later peak (~2–4 h), longer tail (~5–8 h) — “gentler spike, longer babysit” narrative vs Humalog. trial
  • Basal (Lantus-class) feel: No sharp peak; multi-hour to ~24 h coverage discussed for all-day high-food / GH-glucose lore — different risk shape (prolonged lows if food fails). trial

Around the dose 1

  • One training account: biggie_smalls411 described workout fullness through the day and an episode of weakness and shaking attributed to hypoglycemia despite the same food-and-shake routine. Testosterone, NPP, HGH, supplements and training confound attribution; the account does not establish a safe routine. forum

Cycles people discuss 9

  • Not a classic BPC-style injury cycle: Use is event-timed (training days / meals), not a continuous multi-week “peptide course” with a fixed on/off for tissue healing. forum
  • Pulse / training-day structure: Most common pattern is insulin only on hard training days around the workout meal, off rest days. forum
  • Bulk-block experiments: Logs often nest insulin inside 2–4+ week (sometimes ~4–12 week) high-calorie bulk phases already running AAS ± GH. forum
  • Continuous daily multi-week basal use: Discussed in advanced high-food / GH contexts (Lantus-class), not as a first experiment. forum
  • On/off variants in protocol essays: Some secondary writeups suggest periodic time off (e.g., weeks off after weeks on) or adding metformin on some days as a glucose-management co-strategy — evidence for superiority is lore. forum
  • Circumstances flagged as dangerous: Unexpected hypoglycemia, illness, vomiting, missed/delayed meals, unplanned heavy cardio, disrupted travel routines and alcohol appear in warning-oriented discussion. These are not an injection decision rule or a replacement for individualized prescribed-diabetes sick-day care. forumtrial
  • PCT distinction: Community notes distinguish insulin from the AAS/SERM post-cycle-therapy model. After an exposure, ongoing or recurrent hypoglycemia remains the acute concern; carbohydrate lore does not establish a safe end to the risk window. forum
  • Stacked exit: If the stack includes suppressive AAS/SARMs, PCT follows those compounds — not the insulin. forum
  • Long-horizon aesthetic risk frame: Chronic high-dose insulin + GH + surplus is repeatedly implicated in “HGH gut / Palumboism / bubble gut” abdominal distension narratives (visceral fat + organomegaly lore) — multi-drug and multi-year context, not a two-week pulse guarantee. forum

Timing 10

  • Food and delayed-risk discussion: Food timing affects risk beyond the injection moment, but neither a meal nor a calculated action window guarantees protection against hypoglycemia. forumtrial
  • Plasma half-life of free insulin: Minutes after IV; practical duration is absorption-limited after subcutaneous injection. trial
  • Rapid-acting analogs (lispro / aspart / glulisine): Approximate SC onset ~5–15 min, peak ~45–75 min (often summarized ~30–90 min), duration ~3–5 hours. Dominant “PWO slin” class. These are inherited class-table shorthands, not universal measured values. Humalog serum Tmax, glucose-lowering action and elimination are different endpoints; no single table defines an individual danger window. trial
  • Short-acting regular (Humulin R / Novolin R): Onset ~30–60 min, peak ~2–4 hours, duration ~5–8 hours (tables sometimes list up to ~6–8 h). trial
  • Intermediate NPH: Onset ~1–2 h, broad peak ~4–12 h, duration ~12–18 h — uncommon as the primary bodybuilding pulse tool. trial
  • Long-acting basal (glargine / Lantus-class): Onset hours, essentially no sharp peak, ~24 h coverage talk. trial
  • Ultra-long basal (degludec / Tresiba-class): Multi-day coverage medically; rare as a “bro PWO” tool, more a clinical basal contrast. trial
  • IM vs SC absorption: Intramuscular delivery can speed absorption and deepen glucose drop vs subcutaneous — especially risky if exercise follows (clinical exercise studies show faster IM thigh absorption and larger glucose fall). trial
  • Site speed lore (SC): Abdomen generally fastest SC absorption, arms intermediate, thigh/buttock slower — relevant for hypo timing, not “local muscle growth.” trial
  • Downstream glucose: Primary measurable effect is blood glucose fall; community and clinical misuse cases focus on point-of-care glucose checks around the window. trial

More on what it is 7

  • Why forums care: Non-diabetic bodybuilding discourse uses low-to-moderate IU rapid/short insulin around workouts and high-carb meals for nutrient partitioning, glycogen refill, fullness, and anti-catabolism — often inside AAS ± GH polypharmacy. forum
  • Sport / detection lore: Historically attractive in some PED circles partly because exogenous insulin is hard to distinguish from endogenous on standard tests; still treated as prohibited PED use in anti-doping frames and carries medical risk independent of testing. forum
  • What it is: Endogenous 51-amino-acid peptide hormone (two chains linked by disulfide bonds) that is the primary regulator of blood glucose; pharmaceutical products are recombinant human insulin or engineered rapid/basal analogs. trial
  • Mechanism talk (plain): Insulin drives GLUT4-mediated glucose uptake into muscle/adipose, supports amino-acid transport, suppresses proteolysis and lipolysis when carbs/protein are present; community frames this as “shuttling food into muscle.” trial
  • Evidence posture: Extremely strong clinical evidence for diabetes care; athletic hypertrophy claims rest mainly on forum logs, mechanism extrapolation, and sparse case-series/misuse literature. Controlled proof that supra-physiologic insulin adds meaningful muscle in healthy adults is lacking. trial
  • Misconception called out in clinical commentary: Insulin is often oversold as a steroid-like mass builder; medical writers emphasize anti-catabolic / nutrient-handling roles more than direct muscle-protein-synthesis stimulation like AAS. trial
  • Risk frame: Severe hypoglycemia can cause seizure, coma or death. Food planning, monitoring or a previously uneventful exposure does not make nonmedical use safe; this is not a mild peptide side-effect profile. trial

Stacks 10

  • Testosterone + GH + insulin (“trinity”): Classic advanced bulk narrative — androgens for mass/strength, GH for lipolysis/IGF-1/recovery look, insulin for disposal/fullness and to counter GH’s diabetogenic push. forum
  • GH + insulin without naming AAS: Same glucose-management and nutrient-partitioning story; “HGH gut” narratives often involve the combination plus huge calories more than either alone. forum
  • IGF-1 LR3 or DES + insulin: Hardcore nutrient-partitioning / hypertrophy layering; additive hypoglycemia is the central warning. forum
  • Food and supplements in the accounts: Dextrose, highly branched cyclic dextrin, juice, gels, candy and whole-food carbohydrate/protein meals appear alongside insulin. This co-use confounds fullness reports and does not validate a mandatory co-therapy formula or safe preparation sequence. forum
  • Rescue-glucose concern: Forum and clinical discussions emphasize access to glucose tablets or other fast carbohydrate when hypoglycemia occurs. This does not make use safe; severe symptoms, seizure or loss of consciousness require emergency help. forumtrial
  • Metformin (Glucophage) co-talk: Secondary protocols sometimes add metformin several days/week for insulin-sensitivity narrative during insulin or GH blocks — not a free pass to raise IU. forum
  • MK-677 adjacency: Appetite and GH-axis elevation can push food and glucose noise higher; stacking with exogenous insulin is advanced confounded territory. forum
  • GLP-1 / dual-agonist caution: Appetite suppression can blunt early hypo hunger cues — community flags extra glucose vigilance if recomp drugs sit next to insulin. forum
  • AAS + insulin: Dominant co-use pattern — ~95% of nondiabetic insulin users also used anabolic steroids in the Ip et al. weightlifting case series; polypharmacy averages were high. trial
  • Alcohol as anti-stack: Ethanol impairs gluconeogenesis and worsens delayed hypo risk — widely treated as a hard no around insulin windows. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage depends on the product: Humalog vial/pen instructions distinguish unopened and in-use containers. Insulin products have specific refrigeration or room-temperature limits and heat/light/freezing cautions; a generic cool/dry research-vial or seller rule is not adequate. trial

Watch for 15

  • Delayed / nocturnal hypos: Hours later if meal under-matched, extra unplanned activity, or alcohol — rapid products can still surprise after the “I feel fine” hour. forum
  • Fat gain / lipogenesis: Insulin is storage-promoting; excess calories + high IU → fat mass, including visceral concerns in long high-food stacks. forum
  • Abdominal hypertrophy / “HGH gut” / Palumboism lore: Prolonged high-dose GH + insulin ± AAS with massive food is repeatedly cited in reviews and community talk as contributing to protruding abdomen (visceral fat, organomegaly, intestinal hypertrophy hypotheses) — multifactorial, not proven as insulin-only. forum
  • Driving / machinery / solo training: Acute neuroglycopenia during the peak window is a practical danger context forums under-emphasize. forum
  • Illness / reduced intake: Illness, vomiting or reduced food can change glucose and hypoglycemia risk. Bodybuilding sick-day lore is not a substitute for an individual diabetes plan and must not be read as a universal instruction to cut or stop prescribed insulin. trialforum
  • Hypoglycemia (primary acute risk): Tremor, sweating, hunger, anxiety, confusion, blurred vision; can progress to seizure, loss of consciousness, coma, death. trial
  • Case-series rate: In Ip et al. (41 nondiabetic weightlifting insulin users), hypoglycemia was reported by most subjects (~56.8%); at least one reported unconsciousness. trial
  • ER / cryptic use cases: Bodybuilders presenting with profound unexplained hypo from undisclosed insulin — iterative glucose resuscitation described in case reports (e.g., Heidet et al. class). trial
  • IM + exercise risk: Faster absorption and larger glucose falls vs SC when muscle is exercised after injection. trial
  • Injection-site reactions: Bruising, pain, lipohypertrophy from same-site reuse, local irritation; lipohypertrophy then makes absorption unpredictable. trial
  • Polypharmacy confound: Near-universal stacking with AAS and many other PEDs in surveyed users makes adverse-event attribution muddy and multiplies total risk. trial
  • Source / legality / diversion: Obtained from friends, gym dealers, or pharmacies (OTC status varies by country); counterfeits, expired product, and broken cold chain add uncertainty. trial
  • Infection / sterile technique: Shared needles, dirty sites, multi-use vial contamination — standard injection risks. trial
  • Not “safer because natural hormone”: Exogenous supra-physiologic pulses in nondiabetics still crash glucose; naturalness is not a risk shield. trial
  • No controlled healthy-adult hypertrophy safety database: Absence of large RCTs proving gym benefit also means sides are documented mainly via case series, ERs, and self-report. trial

Updated: 2026-08-12

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →